Do you see any role for PARP inhibitors in NSCLC given the recent PIN trial of maintenance olaparib did not show significant improvement in PFS?

The short answer is yes, a role for PARP inhibition in NSCLC may still exist for select patients. The Olaparib Maintenance versus Placebo Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer trial (PIN) evaluated the use of olaparib as maintenance therapy in patients who had tumor respon...